Q-omics provides the consensus-scored SPSB4 profile across patient tissues and cancer cell-line models. SPSB4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SPSB4 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, SPSB4 RNA expression shows 15,861 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, and ESCA as cancer lineages where SPSB4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPSB4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPSB4 survival associations across molecular data types. SPSB4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPSB4 RNA expression–survival associations across cancer types. High SPSB4 expression shows unfavorable associations in KIRP, BLCA, LUSC, ACC and THCA, but favorable associations in UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SPSB4 RNA expression.
This table summarizes SPSB4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SPSB4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPSB4 shows lower tumor expression in KIRP, KIRC and LIHC and higher tumor expression in HNSC, KICH and UCEC. The KIRP box plot shows higher SPSB4 RNA expression in normal versus tumor tissue (log2 FC = −0.915, t-test p < 0.001).
This table shows molecular features associated with SPSB4 in patient tissues and cancer cell lines. In patient samples, SPSB4 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPSB4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
